P-cadherin is a protein commonly found on malignant cancer cells and has been used as a target for antibody-based cancer treatments. UC Davis biomedical engineers have discovered that when an antibody ...
An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...
The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...
WHAT: Researchers from the Johns Hopkins Kimmel Cancer Center will present new research findings and receive honors and ...
Surufatinib combined with TAS-102 as a late-line therapy in patients with metastatic pancreatic cancer (mPDAC): Updated results of a single-arm, phase II trial. Interim analysis of feasibility, safety ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results